1. Home
  2. EBF vs CTNM Comparison

EBF vs CTNM Comparison

Compare EBF & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$22.62

Market Cap

538.9M

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$8.22

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBF
CTNM
Founded
1909
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
538.9M
550.7M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
EBF
CTNM
Price
$22.62
$8.22
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $22.14
AVG Volume (30 Days)
144.1K
★ 1.3M
Earning Date
09-21-2026
11-02-2026
Dividend Yield
★ 4.58%
N/A
EPS Growth
★ 7.79
0.46
EPS
★ 0.76
N/A
Revenue
N/A
N/A
Revenue This Year
$1.01
N/A
Revenue Next Year
$0.92
N/A
P/E Ratio
$30.11
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$16.30
$6.73
52 Week High
$23.09
$17.79

Technical Indicators

Market Signals
Indicator
EBF
CTNM
Relative Strength Index (RSI) 58.09 33.47
Support Level $19.92 N/A
Resistance Level $22.91 $13.72
Average True Range (ATR) 0.37 0.99
MACD 0.00 -0.11
Stochastic Oscillator 56.36 21.74

Price Performance

Historical Comparison
EBF
CTNM

About EBF Ennis Inc.

Ennis Inc is a trade printer company that manufactures a broad range of printed products throughout the United States. It is engaged in the business of manufacturing, designing, and selling business forms and other printed business products to distributors located in the United States. Through a network of independent distributors, its channel encompasses independent print distributors, commercial printers, direct mail, fulfillment companies, payroll and accounts payable software companies, and advertising agencies, among others. The group operates in a single reportable segment called Print and derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: